Cellular and molecular mechanisms of AKI

Anupam Agarwal, Zheng Dong, Raymond Harris, Patrick Murray, Samir M. Parikh, Mitchell H. Rosner, John A. Kellum, Claudio Ronco

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

In this article, we review the current evidence for the cellular and molecular mechanisms of AKI, focusing on epithelial cell pathobiology and related cell-cell interactions, using ischemic AKI as a model. Highlighted are the clinical relevance of cellular and molecular targets that have been investigated in experimental models of ischemic AKI and how such models might be improved to optimize translation into successful clinical trials. In particular, development of more context-specific animal models with greater relevance to human AKI is urgently needed. Comorbidities that could alter patient susceptibility to AKI, such as underlying diabetes, aging, obesity, cancer, and CKD, should also be considered in developing these models. Finally, harmonization between academia and industry for more clinically relevant preclinical testing of potential therapeutic targets and better translational clinical trial design is also needed to achieve the goal of developing effective interventions for AKI.

Original languageEnglish (US)
Pages (from-to)1288-1299
Number of pages12
JournalJournal of the American Society of Nephrology
Volume27
Issue number5
DOIs
StatePublished - May 2016

Fingerprint

Clinical Trials
Cell Communication
Comorbidity
Industry
Theoretical Models
Animal Models
Obesity
Epithelial Cells
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Agarwal, A., Dong, Z., Harris, R., Murray, P., Parikh, S. M., Rosner, M. H., ... Ronco, C. (2016). Cellular and molecular mechanisms of AKI. Journal of the American Society of Nephrology, 27(5), 1288-1299. https://doi.org/10.1681/ASN.2015070740

Cellular and molecular mechanisms of AKI. / Agarwal, Anupam; Dong, Zheng; Harris, Raymond; Murray, Patrick; Parikh, Samir M.; Rosner, Mitchell H.; Kellum, John A.; Ronco, Claudio.

In: Journal of the American Society of Nephrology, Vol. 27, No. 5, 05.2016, p. 1288-1299.

Research output: Contribution to journalReview article

Agarwal, A, Dong, Z, Harris, R, Murray, P, Parikh, SM, Rosner, MH, Kellum, JA & Ronco, C 2016, 'Cellular and molecular mechanisms of AKI', Journal of the American Society of Nephrology, vol. 27, no. 5, pp. 1288-1299. https://doi.org/10.1681/ASN.2015070740
Agarwal A, Dong Z, Harris R, Murray P, Parikh SM, Rosner MH et al. Cellular and molecular mechanisms of AKI. Journal of the American Society of Nephrology. 2016 May;27(5):1288-1299. https://doi.org/10.1681/ASN.2015070740
Agarwal, Anupam ; Dong, Zheng ; Harris, Raymond ; Murray, Patrick ; Parikh, Samir M. ; Rosner, Mitchell H. ; Kellum, John A. ; Ronco, Claudio. / Cellular and molecular mechanisms of AKI. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 5. pp. 1288-1299.
@article{de8c41ae71da40d89fa1568bb912ea0b,
title = "Cellular and molecular mechanisms of AKI",
abstract = "In this article, we review the current evidence for the cellular and molecular mechanisms of AKI, focusing on epithelial cell pathobiology and related cell-cell interactions, using ischemic AKI as a model. Highlighted are the clinical relevance of cellular and molecular targets that have been investigated in experimental models of ischemic AKI and how such models might be improved to optimize translation into successful clinical trials. In particular, development of more context-specific animal models with greater relevance to human AKI is urgently needed. Comorbidities that could alter patient susceptibility to AKI, such as underlying diabetes, aging, obesity, cancer, and CKD, should also be considered in developing these models. Finally, harmonization between academia and industry for more clinically relevant preclinical testing of potential therapeutic targets and better translational clinical trial design is also needed to achieve the goal of developing effective interventions for AKI.",
author = "Anupam Agarwal and Zheng Dong and Raymond Harris and Patrick Murray and Parikh, {Samir M.} and Rosner, {Mitchell H.} and Kellum, {John A.} and Claudio Ronco",
year = "2016",
month = "5",
doi = "10.1681/ASN.2015070740",
language = "English (US)",
volume = "27",
pages = "1288--1299",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Cellular and molecular mechanisms of AKI

AU - Agarwal, Anupam

AU - Dong, Zheng

AU - Harris, Raymond

AU - Murray, Patrick

AU - Parikh, Samir M.

AU - Rosner, Mitchell H.

AU - Kellum, John A.

AU - Ronco, Claudio

PY - 2016/5

Y1 - 2016/5

N2 - In this article, we review the current evidence for the cellular and molecular mechanisms of AKI, focusing on epithelial cell pathobiology and related cell-cell interactions, using ischemic AKI as a model. Highlighted are the clinical relevance of cellular and molecular targets that have been investigated in experimental models of ischemic AKI and how such models might be improved to optimize translation into successful clinical trials. In particular, development of more context-specific animal models with greater relevance to human AKI is urgently needed. Comorbidities that could alter patient susceptibility to AKI, such as underlying diabetes, aging, obesity, cancer, and CKD, should also be considered in developing these models. Finally, harmonization between academia and industry for more clinically relevant preclinical testing of potential therapeutic targets and better translational clinical trial design is also needed to achieve the goal of developing effective interventions for AKI.

AB - In this article, we review the current evidence for the cellular and molecular mechanisms of AKI, focusing on epithelial cell pathobiology and related cell-cell interactions, using ischemic AKI as a model. Highlighted are the clinical relevance of cellular and molecular targets that have been investigated in experimental models of ischemic AKI and how such models might be improved to optimize translation into successful clinical trials. In particular, development of more context-specific animal models with greater relevance to human AKI is urgently needed. Comorbidities that could alter patient susceptibility to AKI, such as underlying diabetes, aging, obesity, cancer, and CKD, should also be considered in developing these models. Finally, harmonization between academia and industry for more clinically relevant preclinical testing of potential therapeutic targets and better translational clinical trial design is also needed to achieve the goal of developing effective interventions for AKI.

UR - http://www.scopus.com/inward/record.url?scp=84977524014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977524014&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015070740

DO - 10.1681/ASN.2015070740

M3 - Review article

C2 - 26860342

AN - SCOPUS:84977524014

VL - 27

SP - 1288

EP - 1299

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -